Navigation Links
Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol

he chemotherapy drug Taxol appears to effectively kill breast cancer cells.

Taxol, used to treat a wide spectrum of cancers, works by interrupting the reorganization of the cell that is necessary if it is to divide. While it was known that the primary effect of the drug is to interfere with assembly of the spindle that pulls nuclear chromosomes apart during cell division, Ueno and his colleagues have recently reported that increased activity of CDK1 correlated with a cell's sensitivity to Taxol.

The CDK enzyme plays a role in cell division, and researchers believe that it functions in part as a monitor of cell cycle activity. Ueno theorizes that if something goes wrong during division - such as if Taxol is interrupting spindle assembly - CDK will become more active in an attempt to correct the problem.

Working with the Sysmex Corporation of Kobe, Japan, the researchers devised a test to measure CDK activity and the expression, simultaneously.

They found that monitoring of two isotypes of CDK activity accurately predicted which tumors would respond to Taxol in the experiments with human breast cancer cell lines and tumor tissues of human xenograft model.

"This provides solid preclinical evidence that we can use toward development of a novel device that can measure CDK activity in human tissue within several hours," Ueno says. He adds that a clinical trial is currently under way that tests CDK activity both before and after patients with breast cancer are treated with Taxol.


'"/>

Source:University Of Texas M. D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. Measuring the impact of post-genomics on Mediterranean populations
2. Measuring hormone cuts antibiotic use in half in pneumonia patients
3. Measuring hidden parasites in falciparum malaria
4. Measuring artery repair cells could become new heart disease test
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Jump-starting T Cells In Skin Cancer
7. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Breakthrough Microarray-based Technology for the Study of Cancer
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
Post Your Comments:
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... of Texas at Austin researchers have demonstrated a new ... the heart and limbs a research advancement that ... disease, the leading cause of death in the Western ... of Engineering Assistant Professor Aaron Baker could allow doctors ...
... available in German . The Deutsche ... four new Research Units. This decision was taken by the ... of the research consortia is to offer researchers the opportunity ... and to establish innovative research directions. As with ...
... University scientists have created the first three-dimensional living tissue ... effectiveness of therapeutics to combat brain tumors. The 3-D ... Petri dish tissue cultures. The researchers created a ... vessels that surrounds it. In a series of experiments, ...
Cached Biology News:New ability to regrow blood vessels holds promise for treatment of heart disease 2New ability to regrow blood vessels holds promise for treatment of heart disease 3DFG to establish 4 new research units 2DFG to establish 4 new research units 3Researchers make living model of brain tumor 2
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & Metabolomics Meeting ... start-up company Asymmetrex to share the first report on progress with its ... for counting adult tissue stem cells. , With a name like “H2A.Z asymmetry,” the ...
Breaking Biology Technology:Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... UK medical technology company,BioCeramic Therapeutics Ltd is delighted ... company,s Board of Directors. Dr Rietiker is widely ... sectors,particularly as former President and CEO of Centerpulse ... of another renowned,figure, Sir Richard Sykes, as Chairman ...
... 8, 2008 From the structure of DNA to ... as abundant as they are useful in nature and ... and Applied Sciences (SEAS) have discovered a way to ... tiny hairs, into helical clusters and have further demonstrated ...
... Inc.,(Nasdaq: OREX ) today announced that ... its,lead investigational product Contrave(R) (naltrexone sustained release,(SR)/bupropion SR) ... a,significant reduction in body weight, improvements in markers ... measures. , In this ...
Cached Biology Technology:Dr Stephan Rietiker Joins BioCeramic Therapeutics 2Researchers control the assembly of nanobristles into helical clusters 2Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 2Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 3Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 4Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 5Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 6Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 7
...
... 96 Well BAC Prep; Ideal ... from 1.5ml 2xYT cultures; Provides ... fluorescent sequencing for small to ... strategy which minimizes shearing and ...
... Mouse monoclonal [SPM278] to 67kD Laminin Receptor, ... carcinoma N592 live cells (Human). Reactivity ... yet tested in other species. Background ... glycoproteins of basement membrane, displays multiple biological ...
Mouse Anti-Lamin B...
Biology Products: